نتایج جستجو برای: certolizumab pegol
تعداد نتایج: 885 فیلتر نتایج به سال:
TNF inhibitors (TNFi) have been in use in clinical practice for the treatment of rheumatoid arthritis (RA) since 1998. The first to be licensed was etanercept, a fusion protein consisting of two soluble p75-TNF-receptor domains and the constant fragment of immunoglobulin. Next was the chimeric mouse human antibody infliximab (the first TNFi to be trialed in man) and later the fully human antibo...
PURPOSE New treatments with novel mechanisms of action and non-overlapping toxicities are needed for patients with metastatic breast cancer. Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a unique toxicity profile. The randomized phase 3 BEACON study that compared EP to treatment of physician's choice (TPC) demonstrated its clinical activity. We now present detailed saf...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید